Inhibitory effects of formoterol and terbutaline on the development of late phase skin reactions.
The capacity of the beta 2-agonist terbutaline and the longer-acting beta 2-agonist formoterol to suppress the development of late phase skin reactions to anti-human IgE was evaluated in 17 healthy volunteers. Anti-IgE injected intradermally per se induced an early weal and flare reaction, followed by a progressively increasing induration, the LCR, with a duration of greater than or equal to 24 hr. The LCR was inhibited by 40% when the weal was infiltrated with formoterol 250 ng 30 min after challenge (n = 9, P less than 0.01). The same anti-LCR effect was achieved by compensating for the shorter duration of action of terbutaline with repeated drug infiltration in 12.5 micrograms doses of the weal produced by anti-IgE up to 3 1/2 hr after challenge (n = 8). The data support the hypothesis that beta 2-agonists, both short- and long-acting, inhibit IgE-dependent LCRs by preferentially interacting with inflammatory events after the initial mast cell degranulation.
Grönneberg
R
R
Department of Lung Medicine, Huddinge University Hospital, Sweden.
Zetterström
O
O
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007073:Immunoglobulin E / Q000276:immunology; D008875:Middle Aged; D012867:Skin / Q000276:immunology*; D012882:Skin Tests; D013726:Terbutaline / Q000494:pharmacology*
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000888:Antibodies, Anti-Idiotypic; D004983:Ethanolamines; C026408:anti-IgE antibodies; D007073:Immunoglobulin E; D013726:Terbutaline; D000068759:Formoterol Fumarate